AMW signs License and Supply Agreement for Commercialization of its Goserelin and Leuprorelin implants in Israel

AMW GmbH, a specialty pharmaceutical company focused on innovative drug delivery systems, today announced that it has entered into license and supply agreements (LSA) with an undisclosed partner for the commercialization of its goserelin and leuprorelin implants in the country of Israel.

read more

In January 2014, AMW GmbH was able to conclude a semi-exclusive license and supply contract for its biodegradable goserelin implants with a multinational pharmaceutical company.

The contract applies to Southeast Asia, including China, Eastern Europe, Russia and some Western European countries. The agreements contain down payment payments of up to € 10 million, license payments in the double-digit percentage range, and an exclusive delivery agreement for AMW. The partner company will carry out further clinical developments for the contract area.

read more